Daewoong pharmaceutical Co.,Ltd

069620.KS

₩113,900.00

+0.09%

2026-08-03 15:17:35 GMT+9+₩100.00

Healthcare

Drug Manufacturers - Specialty & Generic

KSC

Active Trading

Established in 1945 and headquartered in Seoul, South Korea, Daewoong Pharmaceutical Co., Ltd. is a global entity dedicated to the research, production, ...

Price Action of 069620.KS

₩113,900.00

+0.09%+₩100.00

High—

Low—

52W High-42.9%

Rel. vol—

Interval

Range6.1h

Volume—SMA5SMA10

—

Key Metrics of 069620.KS

Snapshot

Latest / TTM · 6 periods

Market Cap

₩1.31T

ROCE

11.4%

EV / EBITDA

8.24x

+0.3% YoY

FCF Yield

-8.8%

-6.7% YoY

Cash Conversion Cycle

163.1d

Current Ratio

0.89

Quick take

Financial Highlights of 069620.KS

Profitability trend

Latest / TTM · 6 periods

Gross Margin

51.6%

Net Margin

12.0%

P/E Ratio

6.83x

n/a

Debt / Equity

0.87

n/a

Current Ratio

0.89

Dividend Yield

0.5%

Understanding

Calendar of 069620.KS

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS KRW 0.00 · Revenue KRW 445.09B
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS KRW 0.00 · Revenue KRW 393.31B

Financial Statements of 069620.KS

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
The total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).

Leadership Team of 069620.KS

3 executives

Name	Title	Compensation	Gender	Year Born	Status
Chang-Jae Lee	Chief Executive Officer & Executive Director	KRW 650,000,000	Male	1977	Active
Seongsoo Park	Chief Executive Officer & Executive Director

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	17021.00 vs 14088.04	+20.8%	—	—
Revenue Surprise	$1570.9B vs $1531.2B	+2.6%	$448.5B vs $422.1B	+6.2%

No matching stocks found

Daewoong pharmaceutical Co.,Ltd

Price Action of 069620.KS

Key Metrics of 069620.KS

Financial Highlights of 069620.KS

Calendar of 069620.KS

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Financial Statements of 069620.KS

Leadership Team of 069620.KS

Key Metrics of 069620.KS

Financial Highlights of 069620.KS

Calendar of 069620.KS

Upcoming

Q3 FY2026 · Estimated results

Q4 FY2026 · Estimated results

Financial Statements of 069620.KS

Leadership Team of 069620.KS

FY2026 · Estimated annual results

Q1 FY2027 · Estimated results

Recent history

Q2 FY2026 · Results reported

Q1 FY2026 · Results reported

FY2025 · Annual results

Q3 FY2025 · Results reported

Q2 FY2025 · Results reported

Q1 FY2025 · Results reported